Rivaroxaban Monotherapy for Atrial Fibrillation and Coronary Artery Disease in Underweight/Obese Patients: Evidence Is Needed

JACC Asia. 2022 Dec 15;2(7):894-896. doi: 10.1016/j.jacasi.2022.09.008. eCollection 2022 Dec.

Authors

Dao Zhou¹, Jiaqi Fan¹, Xianbao Liu¹

Affiliation

¹ Department of Cardiology, Second Affiliated Hospital Zhejiang University School of Medicine, Hangzhou, People's Republic of China.

No abstract available

Keywords: atrial fibrillation; coronary artery disease; obese; underweight.

Publication types

Editorial